RABL6A Promotes Oxaliplatin Resistance in Tumor Cells and Is a New Marker of Survival for Resected Pancreatic Ductal Adenocarcinoma Patients

Pancreatic ductal adenocarcinoma (PDAC) is characterized by early recurrence following pancreatectomy, rapid progression, and chemoresistance. Novel prognostic and predictive biomarkers are urgently needed to both stratify patients for clinical trials and select patients for adjuvant therapy regimen...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Muniz, Viviane P., Askeland, Ryan W., Zhang, Xuefeng, Reed, Sara M., Tompkins, Van S., Hagen, Jussara, McDowell, Bradley D., Button, Anna, Smith, Brian J., Weydert, Jamie A., Mezhir, James J., Quelle, Dawn E.
Formato: Artigo
Idioma:Inglês
Publicado em: SAGE Publications 2013
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3807645/
https://ncbi.nlm.nih.gov/pubmed/24167655
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1947601913501074
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados